- Conditions
- Influenza
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Insight Therapeutics, LLC
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 575
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza A Subtype H5N1 Infection
- Interventions
- Pandemic Influenza Vaccine, Placebo
- Biological
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 19 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Influenza
- Interventions
- Live attenuated influenza vaccine (LAIV4), Inactivated Influenza Vaccine (IIV4)
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Influenza Virus
- Interventions
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 6 Months to 71 Months
- Enrollment
- 10,644 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 91
- States / cities
- Chandler, Arizona • Harrisburg, Arkansas • Anaheim, California + 70 more
- Conditions
- COVID-19
- Interventions
- Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo
- Combination Product · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 9
- States / cities
- Anniston, Alabama • Rolling Hills Estates, California • Hialeah, Florida + 5 more
- Conditions
- Influenza
- Interventions
- Influenza Vaccine, recombinant Hemagglutinin
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 3
- States / cities
- Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
- Conditions
- Influenza
- Interventions
- mRNA-1010, mRNA-1010.4, mRNA-1010.6
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 10
- States / cities
- Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
- Conditions
- Influenza
- Interventions
- PanBlok, rHA adjuvant
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 341 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 5
- States / cities
- Omaha, Nebraska • Rochester, New York • Austin, Texas + 2 more
- Conditions
- Haemophilus Influenzae Type b
- Interventions
- GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™, Pediarix™, Prevnar 13™, Rotarix™, Engerix™-B, Infanrix™
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 4,003 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 63
- States / cities
- Dothan, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 59 more
- Conditions
- Hepatitis A
- Interventions
- Havrix™, Infanrix™, ActHIB™
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 13 Months
- Enrollment
- 468 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Oakland, California • San Ramon, California + 18 more
- Conditions
- Pediatric Solid Organ Transplant Patients
- Interventions
- High-Dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Influenza
- Interventions
- Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
- Conditions
- Influenza, Human
- Interventions
- Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 971 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 15
- States / cities
- Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more
- Conditions
- Influenza Vaccination
- Interventions
- Opting Out
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Galveston, Texas • Houston, Texas
- Conditions
- Influenza
- Interventions
- VRC-FLUNPF081-00-VP (HA-F A/Sing), VRC-FLUDNA082-00-VP (DNA A/Sing)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Influenza
- Interventions
- Nitazoxanide, Placebo
- Drug
- Lead sponsor
- Romark Laboratories L.C.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 17
- States / cities
- Hot Springs, Arkansas • Anaheim, California • Fresno, California + 14 more
- Conditions
- Egg Allergy
- Interventions
- Trivalent Influenza Vaccine
- Biological
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 6 Months to 24 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Interventions
- High-Dose Inactivated, Split-Virion Influenza Vaccine, Inactivated, Split-Virion Influenza Vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 3,851 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 28
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tempe, Arizona + 25 more
- Conditions
- Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
- Interventions
- TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC)
- Biological · Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Immunization; Infection|Transplantation Infection|Influenza, Influenza
- Interventions
- Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine
- Biological
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Influenza, Human
- Interventions
- Seqirus QIV, Comparator QIV
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 2,278 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 32
- States / cities
- Huntsville, Alabama • Madera, California • Ontario, California + 29 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
- Biological · Drug · Other
- Lead sponsor
- Jennifer Woyach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Fever After Vaccination, Fever, Seizures Fever
- Interventions
- mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more
- Conditions
- Seasonal Influenza
- Interventions
- Planning Prompt, Default Appointment, Control
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania